INT149298

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.82
First Reported 2008
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.52
Pain Relevance 0.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (NRP1) cytosol (NRP1) signal transduction (NRP1)
extracellular region (NRP1) cell adhesion (NRP1) plasma membrane (NRP1)
Anatomy Link Frequency
cleavage 2
plasma 1
NRP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 9 99.78 Very High Very High Very High
cINOD 3 93.68 High High
Abeta 9 86.24 High High
antagonist 9 53.40 Quite High
ischemia 6 51.24 Quite High
addiction 9 5.00 Very Low Very Low Very Low
Restless leg syndrome 3 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
Inflammation 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Peripheral Arterial Disease 54 99.02 Very High Very High Very High
Congenital Anomalies 1 95.20 Very High Very High Very High
INFLAMMATION 4 93.28 High High
Cognitive Disorder 1 91.36 High High
Alzheimer's Dementia 2 82.32 Quite High
Injury 3 78.24 Quite High
Disease 25 77.84 Quite High
Targeted Disruption 2 77.04 Quite High
Eclampsia 9 66.68 Quite High
Vasculitis 3 65.64 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Abnormal plasma levels of MMPs in PAD [148], [149] may suggest a role for proteolytic degradation or release of VEGF165 in causing pathological bioavailabilities of VEGF.
Protein_catabolism (degradation) of VEGF165 in plasma associated with peripheral arterial disease
1) Confidence 0.82 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.21 Pain Relevance 0.13
Moreover, interstitial proteolytic clearance of soluble or matrix-bound VEGF – e.g., plasmin- and matrix metalloproteinase (MMP)-mediated cleavage of VEGF165 and the respective release of VEGF110 and VEGF113 fragments [95], [146], as well as the intrinsic protein degradation rate of VEGF [147] – was not considered in the current model.
Protein_catabolism (cleavage) of VEGF165 in cleavage associated with metalloproteinase
2) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.33 Pain Relevance 0.17
Proteolytic shedding of sVEGFR1 from abluminal surface VEGFR1 was neglected in our model, as was VEGF165 proteolysis by plasmin and MMPs [66].
Protein_catabolism (proteolysis) of VEGF165
3) Confidence 0.54 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.05 Pain Relevance 0.03
These toxic effects are likely due to inhibition of Notch cleavage, a transmembrane receptor involved in regulating cell-fate decisions.
Protein_catabolism (cleavage) of transmembrane receptor in cleavage
4) Confidence 0.07 Published 2008 Journal Curr Top Med Chem Section Abstract Doc Link 18220933 Disease Relevance 0.93 Pain Relevance 0.44

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox